CBD and THCV on glycemic and lipid parameters in type 2 diabetes: RCT

Introduction and clinical context

The study CBD and THCV on glycemic and lipid parameters in type 2 diabetes: RCT (Diabetes Care · 2016) is part of the scientific research on the use of cannabinoids in diabetes and metabolic.

In type 2 diabetes and metabolic syndrome, lesser-known cannabinoids — such as THCV — and cannabidiol (CBD) are investigated for possible effects on glycemic control and the metabolic profile. A pilot trial suggested glycemic improvement with THCV, and reviews discuss the role of the endocannabinoid system in metabolism. The evidence is preliminary, and diabetes treatment should follow established practices.

Understanding what science shows about the use of cannabinoids in diabetes and metabolic helps patients and healthcare professionals make safer, well-founded decisions, based on evidence rather than common sense.

Methodology and findings

This clinical trial was conducted in a controlled manner, comparing the treatment with a reference group. Double-blind pilot RCT: THCV improved glycemic control in patients with type 2 diabetes. The blinded, controlled design reduces bias and increases the reliability of the finding. Results from controlled trials like this are especially valuable for guiding therapeutic decisions.

Mechanism of action and safety

In metabolism, the endocannabinoid system regulates appetite, insulin sensitivity and adipogenesis. THCV is investigated for a possible effect of improving glycemic control, with a profile different from THC, and CBD for anti-inflammatory actions relevant in metabolic syndrome. Safety requires attention to interactions with glucose-lowering drugs and to the cardiovascular profile of the diabetic patient. The evidence is still preliminary and does not replace the established treatment of diabetes (diet, exercise and medication); the cannabinoid is, for now, an object of study, under follow-up.

Regulation in Brazil (Anvisa)

In Brazil, access to cannabis products is regulated by Anvisa — mainly through RDC 660/2022 (patient import with a medical prescription) and the new manufacturing and import framework, RDC 1,015/2026. Any therapeutic use must start from an individualized medical assessment and prescription. This content is informative and scientific and does not replace the guidance of a healthcare professional.

This is informative content produced by Brazcann; for the full methodology and detailed results, consult the original publication (Diabetes Care · 2016). Access to cannabis treatments must always occur through the regulated pathway, with a prescription and medical follow-up.

Frequently asked questions

Does cannabis treat diabetes?

The evidence is preliminary (e.g., THCV in glycemic control); diabetes treatment follows established practices.

What is THCV?

It is a lesser-known cannabinoid, studied for possible metabolic effects.